U.S. DOJ Set to Reshape Marijuana Policy in Landmark Move
The U.S. Department of Justice announced a major shift in drug policy by reclassifying marijuana as a less dangerous drug. This decision could transform the $47 billion marijuana industry by easing research, funding, and tax barriers. It aligns federal policy with state-level legalizations and scientific findings.
The U.S. Department of Justice (DOJ) took a significant step on Thursday by announcing plans to reclassify certain marijuana products as less dangerous. This decision marks one of the most substantial changes to American drug policy in decades.
Although the change does not legalize marijuana nationwide, it could reshape the $47 billion industry, which has faced numerous federal barriers. The DOJ's move aims to reclassify medical marijuana products, currently grouped with highly addictive drugs, to a less restrictive category that includes substances like ketamine and testosterone.
The reclassification is expected to foster research, reduce tax burdens, and ease funding challenges for companies. Acting Attorney General Todd Blanche asserted that this initiative would align federal policy with scientific and medical advances and meet patient needs. The decision follows a December executive order from President Trump, and is anticipated to benefit cannabis businesses significantly by mid-2026.
ALSO READ
-
U.S. Government to Loosen Marijuana Restrictions in Major Drug Policy Shift
-
Historic Marijuana Reform: Legal Landscape Undergoing Major Shift
-
Historic Shift: U.S. Reclassifies Marijuana to Spur Industry Growth
-
U.S. Justice Department's Major Marijuana Reclassification
-
Marijuana Reclassification Shakes Up Cannabis Industry
Google News